

1 **Viral load and infectivity of SARS-CoV-2 in paired respiratory and oral specimens from**  
2 **symptomatic, asymptomatic or post-symptomatic individuals**

3

4 Rebecca L. Tallmadge<sup>a</sup>, Melissa Laverack<sup>a</sup>, Brittany Cronk<sup>a</sup>, Roopa Venugopalan<sup>a</sup>, Mathias  
5 Martins<sup>b</sup>, XiuLin Zhang<sup>a</sup>, François Elvinger<sup>a</sup>, Elizabeth Plocharczyk<sup>c</sup>, Diego G. Diel<sup>a#</sup>

6

7 Affiliations

8

9 <sup>a</sup>Department of Population Medicine and Diagnostic Sciences, Animal Health Diagnostic Center,  
10 Cornell COVID-19 Testing Laboratory, College of Veterinary Medicine, Cornell University,  
11 Ithaca, New York, USA

12 <sup>b</sup>Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine,  
13 Cornell University, Ithaca, New York, USA

14 <sup>c</sup>Cayuga Medical Center, Cayuga Health System, Ithaca, New York, USA

15

16 <sup>#</sup>Address correspondence to: Diego G. Diel, [dgdziel@cornell.edu](mailto:dgdziel@cornell.edu)

17

18

19

## 20 **ABSTRACT**

21 In the present study, we assessed the diagnostic sensitivity and determined the viral load and  
22 infectivity of SARS-CoV-2 in paired respiratory (nasopharyngeal and anterior nares) and oral  
23 samples (saliva and sublingual swab). Samples were collected from 77 individuals of which 75  
24 were diagnosed with COVID-19 and classified as symptomatic (n=29), asymptomatic (n=31), or  
25 post-symptomatic (n=15). Specimens were collected at one time point from each individual,  
26 between day 1 to 23 after the initial COVID-19 diagnosis, and included self-collected saliva (S),  
27 or sublingual (SL) swab, and bilateral anterior nares (AN) swab, followed by healthcare provider  
28 collected nasopharyngeal (NP) swab. Sixty-three specimen sets were tested using five  
29 assay/platforms. The diagnostic sensitivity of each assay/platform and specimen type was  
30 determined. Of the 63 specimen sets, SARS-CoV-2 was detected in 62 NP specimens, 52 AN  
31 specimens, 59 saliva specimens, and 31 SL specimens by at least one platform. Infectious SARS-  
32 CoV-2 was isolated from 21 NP, 13 AN, 12 saliva, and one SL specimen out of 50 specimen  
33 sets. SARS-CoV-2 isolation was most successful up to 5 days after initial COVID-19 diagnosis  
34 using NP specimens from symptomatic patients (16 of 24 positives, 66.67%), followed by  
35 specimens from asymptomatic patients (5 of 17 positives, 29.41%), while it was not very  
36 successful with specimens from post-symptomatic patients. Benefits of self-collected saliva and  
37 AN specimens balance the loss of sensitivity relative to NP specimens. Therefore, saliva and AN  
38 specimens are acceptable alternatives for symptomatic SARS-CoV-2 diagnostic testing or  
39 surveillance with increased sampling frequency of asymptomatic individuals.

40

41

42 **Importance**

43 The dynamics of infection with SARS-CoV-2 has a significant impact on virus infectivity and in  
44 the diagnostic sensitivity of molecular and classic virus detection tests. In the present study we  
45 determined the diagnostic sensitivity of paired respiratory (nasopharyngeal and anterior nares  
46 swabs) and oral secretions (saliva and sublingual swab) and assessed infectious virus shedding  
47 patterns by symptomatic, asymptomatic or post-symptomatic individuals. Understanding the  
48 diagnostic performance of these specimens and the patterns of infectious virus shedding in these  
49 bodily secretions provides critical information to control COVID-19, and may help to refine  
50 guidelines on isolation and quarantine of positive individuals and their close contacts identified  
51 through epidemiological investigations.

52 **Keywords:** SARS-CoV-2, diagnostic, RT-PCR, anterior nares, saliva, virus isolation

53

54

## 55 **Introduction**

56           The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),  
57 causative agent of coronavirus disease 19 (COVID-19), in December 2019 led to an  
58 unprecedented pandemic that has killed and continues to kill millions of people worldwide (1).  
59 The number of COVID-19 cases increased rapidly since the identification of the virus in Wuhan,  
60 China. The virus presents a basic reproductive rate estimated at 2.2 – 2.68 and an epidemic  
61 doubling time of 6.4 days (2, 3). Retrospective studies indicate that individuals infected with  
62 SARS-CoV-2 and exhibiting symptoms are infectious for approximately 9 days, although the  
63 presence of viral RNA can linger beyond the end of the infectious period (4). An important  
64 characteristic that favors the efficient spread of SARS-CoV-2 is the fact that virus shedding  
65 occurs prior to the onset of symptoms, and it has been estimated that ~44% of the infections  
66 occur while the index case is pre-symptomatic (5, 6). To date, over 247 million COVID-19 cases  
67 have been confirmed across the globe and more than 5 million of these cases have resulted in  
68 death (<https://covid19.who.int/>, accessed on 11/4/2021). Although vaccines are now available,  
69 the virus continues to cause a toll to human health and several countries are undergoing  
70 additional epidemic waves leading to significant public health concerns; especially due to  
71 reluctance of a great proportion of the population to vaccination, evidence of incomplete  
72 protection from vaccination, and the emergence of SARS-CoV-2 variants (7–12). Thus, the  
73 demand for rapid, sensitive, and efficient diagnostic tests remains. A refined understanding of the  
74 SARS-CoV-2 infectious period is also needed for intervention to limit transmission.

75           Transmission of SARS-CoV-2 occurs mainly via aerosols and droplets and infection can  
76 cause broad clinical symptoms in affected individuals (13,  
77 <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>). Because of the

78 respiratory-based mode of transmission and diversity of symptoms, a wide range of specimen  
79 types have been evaluated for the detection of SARS-CoV-2 RNA (14, 15). Overall, moderate to  
80 high rates of detection were found in lower respiratory tract secretions (sputum, bronchoalveolar  
81 lavage fluid), respiratory swabs (nasopharyngeal swabs, nasal swabs, throat swabs, pharyngeal  
82 swabs, oropharyngeal swabs), saliva, feces/rectal swabs, and serum (14, 15). Blood and urine  
83 specimens provided the lowest rates of SARS-CoV-2 RNA detection (14, 15). The Centers for  
84 Disease Control and Prevention recommend an upper respiratory specimen for initial testing of a  
85 suspect SARS-CoV-2 infection, which may include a nasopharyngeal, oropharyngeal, nasal mid-  
86 turbinate, anterior nares, or saliva specimen ([https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)  
87 [ncov/lab/guidelines-clinical-specimens.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)). Collection of NP swabs, OP swabs, NP  
88 washes/aspirates or nasal washes/aspirates require a trained healthcare provider, whereas other  
89 upper respiratory swabs (e.g anterior nares) and saliva specimens may be self-collected, offering  
90 advantages of limiting healthcare provider exposure to the virus and reducing the need and use  
91 for personal protective equipment during collection.

92 In the present study, we compared the clinical performance of three diagnostic assays  
93 (Rheonix COVID-19 MDx assay, EZ-SARS-CoV-2 real-time RT-PCR assay, and the TaqPath  
94 COVID-19 Combo kit assay) and determined the diagnostic sensitivity of paired respiratory  
95 (nasopharyngeal and anterior nares swabs) and oral samples (saliva and sublingual swabs)  
96 collected from symptomatic, asymptomatic, or post-symptomatic individuals. Additionally, we  
97 determined the viral load and compared shedding of infectious virus in the different specimen  
98 types.

99

## 100 **Materials and Methods**

101 **Study design and specimen collection.** Seventy-seven specimen sets were collected for  
102 validation of clinical diagnostic tests under Cayuga Medical Center (CMC) Institutional Review  
103 Board approval 0420EP. The Cornell University Institutional Review Board (IRB) for Human  
104 Participants also reviewed and approved the study (protocol number 2007009706). All patients  
105 agreed to participate and provided verbal consent prior to specimen collection.

106 Nasopharyngeal (NP) specimens were collected by a healthcare provider with 3D-printed  
107 swabs (NP Swab O1, Origin, San Francisco, CA) (16). Anterior nares (AN) swabs were self-  
108 collected under observation. Each patient was provided with a nasal swab and instructed to insert  
109 the swab less than one inch into the anterior nostril and rotate the swab for 10 seconds against the  
110 nasal wall, then repeat the procedure in the counter lateral nostril using the same swab.

111 Sublingual (SL) swabs were collected by instructing the patient to place the swab under the  
112 tongue and rotate it for one minute. Anterior nares and sublingual swabs were collected using  
113 either a nylon tipped sampling swab (ASP Medical Disposable sampling swab 8205, Cardinal  
114 Health, Dublin, OH), a CultureSwab™ Liquid Stuart Single Swab (220099, BD Life Sciences,  
115 Sparks, MD), or a CultureSwab™ Liquid Stuart Double Swab (220109, BD Life Sciences,  
116 Sparks, MD). All swabs were immersed in 800 µl viral transport media immediately after  
117 collection and stored under refrigeration. For saliva (S) collection, patients were instructed not to  
118 eat, drink, or chew gum or tobacco for at least 30 minutes before sampling. Patients were  
119 instructed to drool 3 mL of saliva into a 15 mL conical tube. An inactivating medium containing  
120 guanidine hydrochloride was added to the saliva and mixed by shaking the tightly closed tube.  
121 Each specimen was collected in duplicate and submitted for testing at the CMC testing  
122 laboratory and at the Cornell COVID-19 Testing Laboratory (CCTL).

123 Patients were classified as symptomatic (n=29) if they had a positive COVID-19  
124 diagnostic test within 5 days of sampling and they exhibited any of the following symptoms:  
125 fever, chills, dyspnea, nausea, vomiting, diarrhea, cough, sore throat, fatigue, muscle aches,  
126 congestion, runny nose, new loss of taste or smell. Patients were classified as asymptomatic  
127 (n=31) if they had a positive COVID-19 diagnostic test within 5 days of sampling and they did  
128 not exhibit any of the symptoms listed above. Patients were classified as post-symptomatic  
129 (n=15) if they were sampled more than 5 days after their initial positive COVID-19 RT-PCR  
130 diagnostic test and were no longer presenting symptoms at the time of re-sampling for this study.  
131 Because the asymptomatic cohort was included in this study, specimen collection days were  
132 tracked relative to the first diagnostic test confirming SARS-CoV-2 infection rather than days  
133 since symptom onset.

134 **Nucleic acid extraction.** The MagMax Viral/Pathogen II (MVP II) Nucleic Acid Isolation Kit  
135 (Applied Biosystems, Foster City, CA) was used to extract nucleic acid (NA) from 200 µl of  
136 each specimen. A negative extraction control containing 200 µl viral transport media (Corning,  
137 Corning, NY) was included on every plate. Extractions were processed on the Kingfisher Flex  
138 Magnetic Particle Processor (Thermo Fisher Scientific Inc., Waltham, MA). The resulting  
139 elution volume was 50 µl and the same elution was used for testing with the EZ-SARS-CoV-2  
140 RT-PCR and the TaqPath COVID-19 Combo Kit Multiplex Real-Time RT-PCR assays.

141 **SARS-CoV-2 Detection assays.** The Rheonix COVID-19™ MDx assay (Rheonix Inc., Ithaca,  
142 NY) is an automated endpoint RT-PCR assay that has an Emergency Use Authorization (EUA)  
143 from the U. S. Food and Drug Administration (FDA). The fully automated Rheonix Encompass  
144 MDx® workstation was used as recommended by the manufacturer for this work at the Cayuga  
145 Medical Center, Ithaca, NY. The Rheonix assay targets the N gene of the SARS-CoV-2 genome

146 and includes detection of the human RNase P gene as an internal control. Approximately 0.5 ml  
147 of each specimen type was loaded in the Rheonix Encompass MDx<sup>®</sup> reaction tube and tested.  
148 Negative and positive controls were included in each run. An “error” result indicated that an  
149 error occurred during the run which prevented a valid result interpretation.

150 The EZ-SARS-CoV-2 Real-Time RT-PCR assay (Tetracore, Inc., Rockville, MD) was  
151 performed as indicated by the manufacturer. The EZ-SARS-CoV-2 RT-PCR assay was validated  
152 for NP and AN specimens (17). A positive amplification control provided by the manufacturer  
153 and a negative amplification control was included on every plate.

154 The Thermo Fisher TaqPath COVID-19 Combo Kit Multiplex Real-Time RT-PCR assay  
155 (Thermo Fisher Scientific Inc.) was performed and analyzed as directed by the manufacturer.  
156 COVID-19 Interpretive Software version 1.2 (Applied Biosystems, Foster City, CA) was used to  
157 interpret the results. An “inconclusive” result indicated that only one of the three SARS-CoV-2  
158 targets were detected. This assay is intended for use with NP and AN swabs under an EUA from  
159 the FDA. A positive amplification control provided by the manufacturer and a negative  
160 amplification control was included on every plate.

161 Real-time PCR assays were performed on both ABI 7500 Fast and QuantStudio 5 real-  
162 time PCR instruments (Thermo Fisher Scientific Inc.), using cycling parameters recommended  
163 by the respective manufacturer.

164 **Diagnostic sensitivity.** The diagnostic sensitivity was calculated for each platform by dividing  
165 the number of positive samples within a specimen type by the total number of infected patients.

166 **Virus isolation.** Virus isolation was performed in NP, AN, saliva and sublingual swab samples  
167 under biosafety level 3 (BSL-3) conditions. For this, twenty-four well plates were seeded with  
168 ~75,000 Vero E6/TMPRSS2 cells per well 24 h prior to sample inoculation. Cells were rinsed

169 with phosphate buffered saline (PBS) (Corning<sup>®</sup>) and inoculated with 150 µl of each sample and  
170 inoculum adsorbed for 1 h at 37 °C with 5% CO<sub>2</sub>. Mock-inoculated cells were used as negative  
171 controls. After adsorption, replacement cell culture media (Dulbecco's modified eagle medium  
172 (DMEM) supplemented with 10% fetal bovine serum (FBS), l-glutamine (2 mM), penicillin  
173 (100 U·ml<sup>-1</sup>), streptomycin (100 µg·ml<sup>-1</sup>), and gentamicin (50 µg·ml<sup>-1</sup>) was added and cells  
174 were incubated at 37 °C with 5% CO<sub>2</sub> and monitored daily for cytopathic effect (CPE) for 3  
175 days. Cell cultures with no CPE were frozen, thawed, and subjected to two additional blind  
176 passages/inoculations in Vero E6/TMPRSS2 cell cultures. CPE positive wells and wells with no  
177 CPE at the end of the third passage, were subjected to immunofluorescence staining using  
178 SARS-CoV-2 N-specific mAbs as previously described (18).

179 **Statistical analysis.** Diagnostic sensitivity and result concordance across specimens and  
180 platforms were calculated with Microsoft Excel (Microsoft Office Professional Plus 2019).  
181 GraphPad Prism (version 9.0.2 for Windows, GraphPad Software, San Diego, CA, USA,  
182 [www.graphpad.com](http://www.graphpad.com)) was used to perform testing for normal distribution of cycle threshold (Ct)  
183 values with Shapiro-Wilk tests, comparison of Ct values using Wilcoxon matched-pairs signed  
184 rank tests or Mann-Whitney tests for unpaired comparisons, and to generate plots.

## 185 **Results**

186 **Sample workflow and categorization.** The clinical performance of three molecular SARS-  
187 CoV-2 assays was evaluated on multiple specimen sets (NP, AN, S, and SL) collected from 77  
188 patients. Specimens were obtained in duplicate from 75 patients that had previously tested  
189 positive for SARS-CoV-2 and from two patients with previous negative SARS-CoV-2 test  
190 results (**Fig. 1**). Of the 75 specimen sets collected from patients diagnosed with COVID-19, 68  
191 sets were tested on all 5 platforms under evaluation: Rheonix, the EZ-SARS-CoV-2 assay on two

192 real-time RT-PCR detection systems (ABI 7500 and QuantStudio 5), and the TaqPath COVID-  
193 19 Combo kit on the same two real-time RT-PCR detection systems (ABI 7500 and QuantStudio  
194 5). SARS-CoV-2 was detected by at least one assay/platform in 63 of the 68 sample sets. The  
195 five sample sets in which SARS-CoV-2 was not detected were excluded from further analyses as  
196 shown in **Fig. 1**. Virus isolation was performed on 50 of the 63 paired specimen sets. This  
197 experimental design allowed comparison of the diagnostic sensitivity among all specimen types  
198 and detection assays.

199 To facilitate the interpretation of the results in the context of SARS-CoV-2 infection  
200 dynamics, the 63 patients included in our study were further categorized as symptomatic,  
201 asymptomatic, or post-symptomatic following the criteria described in the Materials and  
202 Methods. The SARS-CoV-2 RT-PCR results obtained from the four specimen types tested across  
203 the three assays and platforms under evaluation are shown for 25 symptomatic patients (**Table**  
204 **1**), 24 asymptomatic patients (**Table 2**), and 14 post-symptomatic patients (**Table 3**). These  
205 individuals had their initial diagnostic test performed 1-23 days before the multiple specimen set  
206 was collected for this study.

207 **Clinical performance of molecular SARS-CoV-2 assays.** The diagnostic sensitivity of each  
208 specimen was evaluated across the different assays and detection platforms used in our study.  
209 The diagnostic sensitivity of each assay performed with specimens from 25 symptomatic patients  
210 is presented in **Table 4**. These specimens were collected between 2 and 5 days after the initial  
211 diagnostic test (mean of 3.42 days) and SARS-CoV-2 was detected in 96% of NP specimens on  
212 the Rheonix platform and in 100% of NP specimens with the EZ-SARS-CoV-2 or TaqPath  
213 COVID-19 real-time RT-PCR assays. SARS-CoV-2 was detected in 92 to 96% of AN and saliva

214 specimens from symptomatic patients across all platforms. In contrast, SARS-CoV-2 detection  
215 was markedly lower in SL specimens, ranging from 40 to 60% across platforms.

216 SARS-CoV-2 was detected by all assays and platforms in all 4 specimens from 7 of the  
217 25 symptomatic patients. In 16 of the 25 symptomatic patients, SARS-CoV-2 was detected in  
218 NP, AN, and saliva specimens by all assays and platforms, whereas detection in SL specimens  
219 was less reliable. The remaining 2 sets of specimens were collected 3 days after the initial  
220 diagnosis, and SARS-CoV-2 was detected most consistently using NP from these patients.

221 The sensitivity of the assays was lower in asymptomatic patients (**Table 5**) than in  
222 symptomatic patients even though they were collected within the same time frame of 1 to 5 days  
223 after the initial diagnostic test (mean 3.41 days). Using NP specimens, the Rheonix platform  
224 detected 96% of asymptomatic patients, while EZ-SARS-CoV-2 and TaqPath COVID-19 real-  
225 time RT-PCR assays detected 92%. Detection of SARS-CoV-2 in AN specimens decreased to  
226 79% on the Rheonix and ranged from 88 to 92% across EZ-SARS-CoV-2 and TaqPath COVID-  
227 19 real-time RT-PCR assays and platforms. The Rheonix platform presented the higher  
228 sensitivity with asymptomatic saliva specimens than AN (83%), whereas the sensitivity of the  
229 TaqPath COVID-19 assay dropped to 75%. The EZ-SARS-CoV-2 assay detected nearly 92% of  
230 saliva specimens on the ABI 7500 Fast platform, but only 83% on the QuantStudio 5 platform.  
231 Detection of SARS-CoV-2 in SL specimens was lower on all platforms, ranging from 25 to 42%.

232 SARS-CoV-2 was detected in all specimen types from 4 of the 24 asymptomatic patients  
233 by all assays and platforms. Thirteen pairs of NP, AN, and saliva specimens from asymptomatic  
234 patients were detected by all assays and platforms. For some asymptomatic samples, the rate of  
235 SARS-CoV-2 detection was very low, even if they were collected 2 days after diagnosis (**Table**  
236 **2**).

237 Diagnostic sensitivity of these SARS-CoV-2 assays using specimens from a cohort of  
238 post-symptomatic patients were lower than the symptomatic or asymptomatic patients (**Table 6**),  
239 with sample collection performed 8.46 days after initial diagnostic test on average (range 4 to 23  
240 days). The Rheonix and EZ-SARS-CoV-2 assay on the ABI 7500 Fast platform detected nearly  
241 86% of post-symptomatic NP specimens, although the other real-time PCR assays and platforms  
242 detected only 57 to 79% of NP specimens. Only approximately 36 to 43% of AN specimens  
243 were detected across the platforms. The EZ-SARS-CoV-2 assay was able to detect 57% of saliva  
244 specimens on the ABI 7500 Fast platform and 50% on the QuantStudio 5 platform; however,  
245 only approximately 36% were detected by the Rheonix and TaqPath COVID-19 assays. SARS-  
246 CoV-2 was only detected in 7 to 14% of post-symptomatic SL specimens.

247 SARS-CoV-2 was not detected in any complete set of paired specimens from post-  
248 symptomatic patients (**Table 3**). SARS-CoV-2 was detected in NP specimens across all  
249 platforms from 8 of 14 post-symptomatic patients. All assays and platforms detected SARS-  
250 CoV-2 in 4 AN specimens, 3 saliva specimens, and 1 SL specimen collected from post-  
251 symptomatic patients.

252 Considering all SARS-CoV-2-positive specimen sets regardless of symptoms, the  
253 Rheonix and EZ-SARS-CoV-2 assay performed on the ABI 7500 Fast platform detected  
254 approximately 94% of NP specimens (**Table 7**). The TaqPath COVID-19 assay detected 92% of  
255 NP specimens on the ABI 7500 Fast platform; on the QuantStudio 5 platform approximately 87  
256 to 89% of NP specimens were detected by either real-time RT-PCR assay. Detection of AN  
257 specimens ranged from approximately 75 to nearly 81% across platforms. The EZ-SARS-CoV-2  
258 assay was able to detect approximately 86% of saliva specimens on the ABI 7500 Fast platform  
259 and 79% on the QuantStudio 5 platform. The Rheonix platform detected approximately 78% of

260 saliva specimens overall. The TaqPath COVID-19 assay detected 73% of saliva specimens,  
261 regardless of platform. At most, 41% of SL specimens were detected by the EZ-SARS-CoV-2  
262 assay on the ABI 7500 Fast platform, and detection decreased to a low of 27% on the Rheonix  
263 platform (**Table 7**).

264 The overall agreement between the 5 platforms evaluated was compiled for each  
265 specimen type, considering all 63 paired specimen sets (**Table 8**). SARS-CoV-2 detection was  
266 highest using NP specimens across platforms at 87.30%, followed by 82.54% of AN specimens,  
267 and 74.60% of saliva specimens. SARS-CoV-2 detection decreased to 61.9% in SL specimens  
268 across platforms.

269 Detection of SARS-CoV-2 RNA was most successful from NP specimens and so the  
270 percent detection relative to NP was determined for the remaining specimen types across  
271 platforms (**Table 9**). SARS-CoV-2 was detected from 79-90% of AN and saliva specimens  
272 relative to NP. However, 95% of saliva specimens were detected relative to NP when detection  
273 from all platforms were combined in contrast to 84% of AN specimens; this was largely due to  
274 positive saliva specimens collected from post-symptomatic patients (**Table 3**). Relative to NP  
275 specimens, SL specimens yielded 52% detection when results from all platforms were combined.

## 276 **Comparison of specimen types for detection of SARS-CoV-2**

277 To further investigate the differences between specimen types, we compared the SARS-  
278 CoV-2 cycle threshold (Ct) value detected by the EZ-SARS-CoV-2 assay on the ABI 7500 Fast  
279 platform. Of the total 63 specimen sets, SARS-CoV-2 was detected in 59 NP specimens, 51 AN  
280 specimens, 54 saliva specimens, and 26 SL specimens (**Fig. 2**). The median Ct value in NP  
281 specimens was 26.13, the median Ct value detected in AN specimens was 26.19, and the median  
282 Ct value was 26.26 in saliva specimens. There was no difference between Ct values obtained

283 from NP, AN, or saliva specimens ( $p \geq 0.1681$ ). However, the median SARS-CoV-2 Ct value  
284 detected in SL specimens was zero, which indicated the lack of SARS-CoV-2 detection. SARS-  
285 CoV-2 Ct values were detected in 26 of the 63 SL specimens and in general they tend to be  
286 higher than those detected in other specimen types. SARS-CoV-2 Ct values obtained from SL  
287 specimens were different from NP, AN, and saliva specimen Ct values ( $p < 0.0030$ ).

288 SARS-CoV-2 Ct values detected by the EZ-SARS-CoV-2 assay on the ABI 7500 Fast  
289 platform were also compared between symptomatic, asymptomatic, and post-symptomatic  
290 groups. No difference was found between symptomatic and asymptomatic groups for Ct values  
291 detected from NP ( $p = 0.2307$ ), AN ( $p = 0.0778$ ), saliva ( $p = 0.2602$ ) or SL ( $p = 0.8490$ ) specimens.  
292 When Ct values determined from specimens collected from post-symptomatic patients were  
293 compared to those of symptomatic or asymptomatic patients, the Ct values in the post-  
294 symptomatic group were higher for NP ( $p < 0.0003$ ) and saliva ( $p < 0.0036$ ) specimens. The  
295 difference in Ct values from post-symptomatic AN specimens neared significance when  
296 compared to symptomatic AN specimens ( $p = 0.0581$ ) but did not differ from asymptomatic AN  
297 specimens ( $p = 0.7547$ ). There were not enough Ct values from post-symptomatic SL specimens  
298 for statistical comparison.

299 To appreciate the dynamics of SARS-CoV-2 Ct values within a patient, only specimen  
300 sets with a Ct value for all 4 specimens from the EZ-SARS-CoV-2 assay on the ABI 7500 Fast  
301 platform were plotted (**Fig. 3**). From these 24 specimen sets, NP samples presented the lowest Ct  
302 values followed by AN ( $p = 0.0014$ ), S ( $p = 0.0194$ ), and SL ( $p < 0.0001$ ) samples. The latter  
303 presented the highest Ct value of all four specimen types ( $p < 0.0001$ , **Fig. 3**).

304 **SARS-CoV-2 infectivity across specimens**

305 SARS-CoV-2 isolation was performed on 50 sets of specimens. The virus was isolated  
306 from 21 of 50 NP, 13 of 50 AN, 12 of 50 saliva, and one SL specimen (**Fig. 4**). SARS-CoV-2  
307 isolation was most successful using specimens from symptomatic patients and isolation was not  
308 successful in specimens from post-symptomatic patients (**Fig.5**). Stratifying successful virus  
309 isolation by specimen type, NP was the specimen with the highest isolation rate, with virus  
310 isolated from 16 of 24 symptomatic and 5 of 17 asymptomatic specimens (**Fig.5A, 5B**). AN was  
311 the next most successful specimen type with virus isolated from 10 of 24 symptomatic and 3 of  
312 17 asymptomatic specimens (**Fig.5A, 5B**). Success of virus isolation using saliva specimens was  
313 similar to AN, with 9 of 24 symptomatic and 3 of 17 asymptomatic yielding infectious virus  
314 (**Fig.5A, 5B**). Virus isolation from SL specimens resulted in only one out of 24 symptomatic and  
315 none of the 17 asymptomatic specimens yielding infectious SARS-CoV-2 when inoculated in  
316 cell culture (**Fig.5A, 5B**). SARS-CoV-2 was not isolated from post-symptomatic patient  
317 specimens (**Fig.5C**).

318 Specimens that yielded infectious SARS-CoV-2 had significantly lower Ct values for  
319 symptomatic NP ( $p=0.0007$ ), AN ( $p<0.0001$ ), and saliva ( $p=0.0009$ ) specimens than specimens  
320 that did not yield infectious virus (**Fig.5A**). Lower SARS-CoV-2 Ct values ( $p\leq 0.0324$ ) were also  
321 detected in asymptomatic specimens that yielded infectious virus in comparison to specimens  
322 that did not yield virus (**Fig.5B**).

323 The success of recovery of infectious SARS-CoV-2 decreased over time, with virus being  
324 recovered from 100% of the samples from symptomatic patients collected 2 days after initial  
325 diagnosis, which declined to 50% of the samples by 5 days (**Fig.5A**). Virus isolation was less  
326 successful from asymptomatic patient specimens, even when collected 1 day after diagnosis,

327 although it was possible to recover SARS-CoV-2 virus from asymptomatic specimens collected  
328 up to 5 days following diagnosis (**Fig.5B**).

329  
330 **Discussion**

331 This study was undertaken to compare the performance of five molecular SARS-CoV-2  
332 assay/platform combinations across paired respiratory (NP and AN swabs) and oral (S and SL  
333 swab) specimens collected from symptomatic, asymptomatic, and post-symptomatic patients. All  
334 five assay/platform combinations assessed in this study are based on RT-PCR. The Rheonix  
335 MDx assay incorporates cell lysis, RNA purification, amplification, and detection steps in a  
336 closed system. For the real-time RT-PCR assays, nucleic acid isolation was performed separate  
337 from amplification, although the same elution was used for all real-time assays. The limit of  
338 detection (LoD) of these assays is similar despite the differences in methodology: the Rheonix  
339 LoD is 625 genomic equivalents per mL, the EZ-SARS-CoV-2 assay LoD is 250 genome  
340 equivalents per mL and the TaqPath COVID-19 assay LoD is 10 genomic equivalents per  
341 reaction or 500 genome equivalents per mL (17, <https://www.fda.gov/media/137489/download>,  
342 Thermo Fisher Scientific Inc. (2020) TaqPath COVID-19 Combo Kit and TaqPath COVID-19  
343 Combo Kit Advanced Instructions for Use, Publication Number MAN0019181, Revision H.0).

344 The comparative diagnostic sensitivity values determined herein revealed that the EZ-  
345 SARS-CoV-2 assay on the ABI 7500 platform was the most sensitive assay/platform  
346 combination. The Rheonix platform followed closely and demonstrated equivalent performance  
347 on NP specimens. The TaqPath COVID-19 assay on the ABI 7500 platform ranked third in  
348 performance. The QuantStudio 5 platform provided lower sensitivity, with the EZ-SARS-CoV-2  
349 assay performing slightly better than the TaqPath COVID-19 assay.

350           Collection of 4 specimens from each patient allowed for direct comparisons of detection  
351 between specimens. NP specimens provided the best rate of detection among specimens  
352 collected from symptomatic and asymptomatic patients across the platforms used herein, with  
353 detection rates of 92 to 100%. NP has been described as the most sensitive specimen in other  
354 studies, even if 100% detection is not achieved (19, 20). This can likely be explained by the fact  
355 that SARS-CoV-2 replicates in nasal turbinates and the NP swab collection procedure harvests  
356 infected turbinate epithelial cells (18, 21). Detection rates of SARS-CoV-2 from AN and saliva  
357 specimens were slightly lower at 92-96% for symptomatic patients, with equivalent performance  
358 across the real-time RT-PCR platforms. However, AN and saliva specimens provided lower  
359 sensitivity when collected from asymptomatic patients (75 to 92%). A meta-analysis of  
360 published data also found a reduced detection rate from nasal swabs (AN or mid-turbinate) and  
361 saliva when compared to NP swabs collected from the same patient (20). This again, could be a  
362 result of the virus tropism and slight differences in viral loads at different replication sites (e.g.  
363 nasal turbinate epithelium vs tonsil). SARS-CoV-2 detection from sublingual swab specimens  
364 was inferior to the other specimens in this study, with detection rates of 40-60% from  
365 symptomatic patient specimens and 25 to 42% from asymptomatic patient specimens.

366           There was only one set of specimens collected from an asymptomatic individual (patient  
367 33, **Table 2**) for which SARS-CoV-2 was not detected in NP on any platform; only saliva and  
368 sublingual swab specimens were positive and only when using the EZ-SARS-CoV-2 assay on  
369 the ABI 7500 platform. Detection of SARS-CoV-2 in saliva samples but not in NP has been  
370 reported for some patients across multiple studies (22–29). Senok and colleagues found that  
371 saliva specimens were especially sensitive in asymptomatic patients (30). It should be noted that  
372 the performance of saliva specimens for SARS-CoV-2 diagnosis differs according to saliva

373 collection and processing methods (20, 23, 31). As expected and reported in the literature neither  
374 NP, nor AN or saliva specimens provide 100% sensitivity (32, 33). Some studies suggest that  
375 discordant results between paired specimens could be due to the distribution of viral replication  
376 specific to that individual (23). Additionally, the dynamics of virus infection and differences in  
377 viral load over time are also important factors that affect diagnostic sensitivity.

378 A strength of this study is the inclusion of symptomatic, asymptomatic, and post-  
379 symptomatic patients, allowing comparison of detection rates between these groups. The rate of  
380 detection of SARS-CoV-2 was highest using specimens from symptomatic patients (92 to 100%  
381 for NP, AN and saliva), followed by asymptomatic patient specimens (75 to 96% for NP, AN  
382 and saliva). Although detection using NP collected from post-symptomatic patients was 86% on  
383 the two most sensitive platforms, the other specimens did not robustly detect SARS-CoV-2 in  
384 post-symptomatic patients.

385 Equivalent SARS-CoV-2 Ct values were obtained from NP, AN, and saliva specimens  
386 when results from all 63 sets were analyzed. Comparable SARS-CoV-2 Ct values from NP and  
387 saliva specimens have also been found in other studies (27, 29, 34–37). Further, no difference  
388 was found when SARS-CoV-2 Ct values were compared between specimens collected from  
389 symptomatic and asymptomatic patients, consistent with other findings based on Ct values (38)  
390 and viral load (39). However, Ct values obtained from post-symptomatic patients NP and saliva  
391 specimens were higher than Ct values from symptomatic or asymptomatic specimens, likely  
392 reflecting a decrease in viral load after the resolution of symptoms and the infection. When the  
393 dataset was narrowed to 24 individuals for which each specimen was positive, differences in  
394 SARS-CoV-2 Ct values between specimens were observed. In this case, the SARS-CoV-2 Ct

395 values detected from NP specimens were lower than those from AN and S, and the Ct values  
396 detected from SL specimens were higher than NP, AN, or S.

397 SARS-CoV-2 isolation was attempted with 50 of 63 positive sample sets and this enabled  
398 additional insights into virus infectivity among specimen types over time. Overall, SARS-CoV-2  
399 isolation was successful in 23.5% of specimens tested. Infectious virus was isolated  
400 predominantly in specimens from symptomatic patients (16 of 25 [64%]). In contrast, infectious  
401 virus was isolated from less than one-third of specimens collected from asymptomatic patients (5  
402 of 17 [29%]). SARS-CoV-2 viral isolation was unsuccessful when specimens from post-  
403 symptomatic patients were tested. Unfortunately, virus isolation was not possible in the original  
404 samples collected from these patients and that resulted in the first diagnosis of SARS-CoV-2  
405 infection, as these specimens were collected in an inactivating guanidine media.

406 SARS-CoV-2 isolation was more successful from NP (21 of 50 [42%]) than AN (13 of  
407 50 [26%]) or saliva (12 of 50 [24%]) specimens in this study. Specimens that yielded viral  
408 isolation were characterized by lower Ct values, corresponding to higher viral load. Lower  
409 SARS-CoV-2 Ct values and viral loads greater than  $10^6$  copies per mL often contribute  
410 successful viral isolation (40–43).

411 Specimens collected up to 5 days after the initial SARS-CoV-2 diagnosis consistently  
412 yielded virus, although SARS-CoV-2 RNA was detected occasionally up to 23 days after  
413 diagnosis in specimens collected from post-symptomatic patients. SARS-CoV-2 shedding is  
414 known to continue up to 48 days (6, 41, 44–46). Recovery of SARS-CoV-2 by culture has been  
415 successful up to 8 days after the onset of symptoms (41, 42, 46). The continued viral RNA  
416 shedding beyond the detection of infectious virus confounds establishing guidelines for releasing  
417 individuals from isolation (47, 48). It is possible that intact viral genomes and “live” particles are

418 present and shed, however, the viral load might be too low for successful virus isolation late in  
419 the course of infection (40, 41, 46).

420 Collectively, this work identified the EZ-SARS-CoV-2 assay on the ABI 7500 platform  
421 as the most sensitive SARS-CoV-2 test across patients segregated by symptomology and across  
422 specimen types. The Rheonix system also demonstrated high diagnostic sensitivity on NP, AN,  
423 and saliva specimens. Although NP specimens provided the highest sensitivity, 86-90% of paired  
424 AN and saliva specimens were detected. As AN and saliva specimens can be self-collected with  
425 minimal PPE, materials, and assistance, they offer alternatives to NP specimens. The robust  
426 detection of SARS-CoV-2 from AN and saliva specimens by the EZ-SARS-CoV-2 assay  
427 supports the use of either specimen in a surveillance program of asymptomatic individuals.

428

429 **Acknowledgements:** We thank all health care workers from Cayuga Medical Center for their  
430 help collecting NP swabs. The work was supported by the Cornell Office of the Vice President  
431 for Research.

432

## 433 References

- 434 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,  
435 Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from  
436 Patients with Pneumonia in China, 2019. *N Engl J Med* 382:727–733.
- 437 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong  
438 JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C,  
439 Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z,  
440 Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ,  
441 Yang B, Leung GM, Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of  
442 Novel Coronavirus–Infected Pneumonia. *N Engl J Med* 382:1199–1207.
- 443 3. Wu JT, Leung K, Leung GM. 2020. Nowcasting and forecasting the potential domestic  
444 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a  
445 modelling study. *Lancet* 395:689–697.
- 446 4. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, Butler F, Griffin J, Lane  
447 EA, McAloon C, O’Brien K, Wall P, Walsh KA, More SJ. 2020. Inferred duration of  
448 infectious period of SARS-CoV-2: rapid scoping review and analysis of available  
449 evidence for asymptomatic and symptomatic COVID-19 cases. *BMJ Open* 10:e039856.
- 450 5. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo  
451 X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling  
452 BJ, Li F, Leung GM. 2020. Temporal dynamics in viral shedding and transmissibility of  
453 COVID-19. *Nat Med* 26:672–675.
- 454 6. Jang S, Rhee JY, Wi YM, Jung BK. 2021. Viral kinetics of SARS-CoV-2 over the  
455 preclinical, clinical, and postclinical period. *Int J Infect Dis* 102:561–565.
- 456 7. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. 2020. Attitudes  
457 Toward a Potential SARS-CoV-2 Vaccine□: A Survey of U.S. Adults. *Ann Intern Med*  
458 173:964–973.
- 459 8. Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, McKay R,  
460 Bennett K, Mason L, Gibson-Miller J, Levita L, Martinez AP, Stocks TVA, Karatzias T,  
461 Hyland P. 2021. Psychological characteristics associated with COVID-19 vaccine  
462 hesitancy and resistance in Ireland and the United Kingdom. *Nat Commun* 12.
- 463 9. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M, Zigran A, Srouji S, Sela E.  
464 2020. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J*  
465 *Epidemiol* 35:775–779.
- 466 10. Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, Blain AE, McClung  
467 N, Campos-Outcalt D, Morgan RL, Mbaeyi S, MacNeil J, Romero JR, Talbot HK, Lee  
468 GM, Bell BP, Dooling K. 2021. The Advisory Committee on Immunization Practices’  
469 Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States,  
470 February 2021. *MMWR Morb Mortal Wkly Rep* 70:329–332.
- 471 11. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW,  
472 Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann

- 473 KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie  
474 T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL,  
475 Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC,  
476 Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M. 2021.  
477 Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19  
478 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First  
479 Responders, and Other Essential and Frontline Workers — Eight U.S. Locations,  
480 December 2020–March . *MMWR Morb Mortal Wkly Rep* 70:495–500.
- 481 12. Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J,  
482 Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai  
483 V, Balazs AB. 2021. Multiple SARS-CoV-2 variants escape neutralization by vaccine-  
484 induced humoral immunity. *Cell* S0092-8674:00298–1.
- 485 13. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. 2021. Transmission of SARS-CoV-  
486 2: A Review of Viral, Host, and Environmental Factors. *Ann Intern Med* 174:69–79.
- 487 14. Bwire GM, Majigo M V., Njiro BJ, Mawazo A. 2021. Detection profile of SARS-CoV-2  
488 using RT-PCR in different types of clinical specimens: A systematic review and meta-  
489 analysis. *J Med Virol* 93:719–725.
- 490 15. Muhammad A, Ameer H, Haider SA, Ali I. 2021. Detection of SARS-CoV-2 using real-  
491 time polymerase chain reaction in different clinical specimens: A critical review. *Allergol*  
492 *Immunopathol (Madr)* 49:159–164.
- 493 16. Callahan CJ, Lee R, Zulauf KE, Tamburello L, Smith KP, Previtera J, Cheng A, Green A,  
494 Azim AA, Yano A, Doraiswami N, Kirby JE, Arnaout RA. 2020. Open development and  
495 clinical validation of multiple 3d-printed nasopharyngeal collection swabs: rapid  
496 resolution of a critical covid-19 testing bottleneck. *J Clin Microbiol* 58:876–896.
- 497 17. Laverack M, Tallmadge RL, Venugopalan R, Cronk B, Zhang X, Rauh R, Saunders A,  
498 Nelson WM, Plocharczyk E, Diel DG. 2021. Clinical evaluation of a multiplex real-time  
499 RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory  
500 tract samples. *Arch Virol* 166:2551–2561.
- 501 18. Palmer M V., Martins M, Falkenberg S, Buckley A, Caserta LC, Mitchell PK, Cassmann  
502 ED, Rollins A, Zylich NC, Renshaw RW, Guarino C, Wagner B, Lager K, Diel DG. 2021.  
503 Susceptibility of white-tailed deer ( *Odocoileus virginianus* ) to SARS-CoV-2. *J Virol*  
504 95:e00083-21.
- 505 19. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S,  
506 Barati S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L,  
507 Zhong XZ, McGeer AJ, Mubareka S, Coleman BL, Chen D, Farshait N, Gold W, Kandel  
508 CE, Katz K, Kozak R, Mazzulli T, Muller M, Opavsky A, Ostrowski M, Plevneshi A, Rau  
509 N, Ricciuto D, Richardson D, Rose D, Sales V, Walmsley S. 2020. Sensitivity of  
510 Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory  
511 Syndrome Coronavirus 2. *Clin Infect Dis* <https://doi.org/10.1093/cid/ciaa848>.
- 512 20. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance of  
513 Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A

- 514 Systematic Review and Meta-analysis. *J Clin Microbiol*  
515 <https://doi.org/10.1128/JCM.02881-20>.
- 516 21. Shou S, Liu M, Yang Y, Kang N, Song Y, Tan D, Liu N, Wang F, Liu J, Xie Y. 2021.  
517 Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-  
518 human Primates. *Front Microbiol* 12:626553.
- 519 22. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M, Sessa F,  
520 Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020. Saliva is a  
521 reliable tool to detect SARS-CoV-2. *J Infect* 81:e45–e50.
- 522 23. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, Lohinai Z, Szakács Z, Hegyi  
523 P, Steward MC, Varga G. 2020. Saliva as a Candidate for COVID-19 Diagnostic Testing:  
524 A Meta-Analysis. *Front Med* 7.
- 525 24. Kandel C, Zheng J, McCready J, Serbanescu MA, Racher H, Desaulnier M, Powis JE,  
526 Vojdani K, Finlay L, Sheldrake E, Vermeiren C, Katz K, McGeer A, Kozak R, Goneau  
527 LW. 2020. Detection of SARS-CoV-2 from Saliva as Compared to Nasopharyngeal  
528 Swabs in Outpatients. *Viruses* 12.
- 529 25. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G,  
530 Suksuwan W, Sungkanuparph S, Phuphuakrat A. 2020. Saliva sample as a non-invasive  
531 specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study. *Clin*  
532 *Microbiol Infect* 27.
- 533 26. Sakanashi D, Asai N, Nakamura A, Miyazaki N, Kawamoto Y, Ohno T, Yamada A, Koita  
534 I, Suematsu H, Hagihara M, Shiota A, Kurumiya A, Sakata M, Kato S, Muramatsu Y,  
535 Koizumi Y, Kishino T, Ohashi W, Yamagishi Y, Mikamo H. 2021. Comparative  
536 evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of  
537 SARS-CoV-2 RNA in Japanese patients with COVID-19. *J Infect Chemother* 27:126–129.
- 538 27. Sun Q, Li J, Ren H, Pastor L, Loginova Y, Madej R, Taylor K, Wong JK, Zhang Z, Zhang  
539 A, Lu CM, Sha MY. 2021. Saliva as a testing specimen with or without pooling for  
540 SARS-CoV-2 detection by multiplex RT-PCR test. *PLoS One* 16:e0243183.
- 541 28. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, Sakai-Tagawa Y,  
542 Iwatsuki-Horimoto K, Shiraki T, Uchida S, Uno S, Kabata H, Ikemura S, Kamata H, Ishii  
543 M, Fukunaga K, Kawaoka Y, Hasegawa N, Murata M. 2021. Accuracy and stability of  
544 saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol*.  
545 BMJ Publishing Group.
- 546 29. Yee R, Truong TT, Pannaraj PS, Eubanks N, Gai E, Jumarang J, Turner L, Peralta A, Lee  
547 Y, Bard JD. 2021. Saliva is a promising alternative specimen for the detection of SARS-  
548 CoV-2 in children and adults. *J Clin Microbiol* 59.
- 549 30. Senok A, Alsuwaidi H, Atrah Y, Ayedi O Al, Zahid J Al, Han A, Marzooqi A Al, Heialy  
550 S Al, Altrabulsi B, Abdelwareth L, Idaghdour Y, Ali R, Loney T, Alsheikh-Ali A. 2020.  
551 Saliva as an alternative specimen for molecular COVID-19 testing in community settings  
552 and population-based screening. *Infect Drug Resist* 13:3393–3399.
- 553 31. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. 2021. The Sensitivity and Costs

- 554 of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs□: A  
555 Systematic Review and Meta-analysis. *Ann Intern Med* [https://doi.org/10.7326/M20-](https://doi.org/10.7326/M20-6569)  
556 6569.
- 557 32. Comber L, Walsh KA, Jordan K, O'Brien KK, Clyne B, Teljeur C, Drummond L, Carty  
558 PG, De Gascun CF, Smith SM, Harrington P, Ryan M, O'Neill M. 2020. Alternative  
559 clinical specimens for the detection of SARS-CoV-2: A rapid review. *Rev Med Virol*.  
560 John Wiley and Sons Ltd.
- 561 33. Nasiri K, Dimitrova A. 2021. Comparing saliva and nasopharyngeal swab specimens in  
562 the detection of COVID-19: A systematic review and meta-analysis. *J Dent Sci*  
563 <https://doi.org/10.1016/j.jds.2021.01.010>.
- 564 34. Altawalah H, AlHuraish F, Alkandari WA, Ezzikouri S. 2020. Saliva specimens for  
565 detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: A cross-sectional  
566 study. *J Clin Virol* 132:104652.
- 567 35. Herrera LA, Hidalgo-Miranda A, Reynoso-Noverón N, Meneses-García AA, Mendoza-  
568 Vargas A, Reyes-Grajeda JP, Vadillo-Ortega F, Cedro-Tanda A, Peñalosa F, Frías-  
569 Jimenez E, Arriaga-Canon C, Ruiz R, Angulo O, López-Villaseñor I, Amador-Bedolla C,  
570 Vilar-Compte D, Cornejo P, Cisneros-Villanueva M, Hurtado-Cordova E, Cendejas-  
571 Orozco M, Hernandez-Morales JS, Moreno B, Hernández-Cruz IA, Herrera CA, García F,  
572 González-Woge MA, Munguía-Garza P, Luna-Maldonado F, Sanchez-Vizcarra A, Osnaya  
573 VG, Medina-Molotla N, Alfaro-Mora Y, Caceres-Gutiérrez RE, Tolentino-Garcia L,  
574 Rosas-Escobar P, Román-González SA, Escobar-Arrazola MA, Canseco-Mendez JC,  
575 Ortiz-Soriano DR, Dominguez-Ortiz J, Gonzalez-Barrera AD, Aparicio-Bautista DI, Cruz-  
576 Rangel A, Alarcón-Zendejas AP, Contreras-Espinosa L, González R, Guerra-Calderas L,  
577 Meraz-Rodríguez MA, Montalvo-Casimiro M, Montiel-Manríquez R, Torres-Arciga K,  
578 Venegas D, Juárez-González V, Guajardo-Barreto X, Monroy-Martínez V, Guillén D,  
579 Fernández J, Herrera J, León-Rodríguez R, Canela-Pérez I, Ruiz-Ordaz BH, Valdez-  
580 Vazquez R, Bertin-Montoya J, Niembro-Ortega M, Villegas-Acosta L, López-Castillo D,  
581 Soriano-Ríos A, Gastelum-Ramos M, Zamora-Barandas T, Morales-Baez J, García-  
582 Rodríguez M, García-Martínez M, Nieto-Patlán E, Quirasco-Baruch M, López-Martínez I,  
583 Ramírez-Gonzalez E, Olivera-Díaz H, Escobar-Escamilla N. 2021. Saliva is a reliable and  
584 accessible source for the detection of SARS-CoV-2. *Int J Infect Dis*  
585 <https://doi.org/10.1016/j.ijid.2021.02.009>.
- 586 36. Tutuncu EE, Ozgur D, Karamese M. 2021. Saliva samples for detection of SARS-CoV-2  
587 in mildly symptomatic and asymptomatic patients. *J Med Virol*  
588 <https://doi.org/10.1002/jmv.26821>.
- 589 37. Yokota I, Hattori T, Shane PY, Konno S, Nagasaka A, Takeyabu K, Fujisawa S, Nishida  
590 M, Teshima T. 2021. Equivalent SARS-CoV-2 viral loads by PCR between  
591 nasopharyngeal swab and saliva in symptomatic patients. *Sci Rep* 11:4500.
- 592 38. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son HJ, Yu S, Park JW, Choo EJ,  
593 Park S, Loeb M, Kim TH. 2020. Clinical Course and Molecular Viral Shedding among  
594 Asymptomatic and Symptomatic Patients with SARS-CoV-2 Infection in a Community  
595 Treatment Center in the Republic of Korea. *JAMA Intern Med*

- 596 <https://doi.org/10.1001/jamainternmed.2020.3862>.
- 597 39. Cereda, D, Tirani, M, Rovida, F, Demicheli, V, Ajelli, M, Poletti, P, Trentini, F, Guzzetta,  
598 G, Marziano, V, Barone, A, Magoni, M, Deandrea, S, Diurno, G, Lombardo, M, Faccini,  
599 M, Pan, A, Bruno, R, Pariani, E, Grasselli, G, Piatti, A, Gramegna, M, Bald MS. 2020.  
600 The early phase of the COVID-19 outbreak in Lombardy, Italy. arXiv 2003.09320.
- 601 40. Huang CG, Lee KM, Hsiao MJ, Yang SL, Huang PN, Gong YN, Hsieh TH, Huang PW,  
602 Lin YJ, Liu YC, Tsao KC, Shih SR. 2020. Culture-based virus isolation to evaluate  
603 potential infectivity of clinical specimens tested for COVID-19. *J Clin Microbiol* 58.
- 604 41. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,  
605 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann  
606 R, Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized  
607 patients with COVID-2019. *Nature* 581:465–469.
- 608 42. Jefferson T, Spencer EA, Brassey J, Heneghan C. 2020. Viral cultures for COVID-19  
609 infectious potential assessment – a systematic review. *Clin Infect Dis*  
610 <https://doi.org/10.1093/cid/ciaa1764>.
- 611 43. Yamada S, Fukushi S, Kinoshita H, Ohnishi M, Suzuki T, Fujimoto T, Saijo M, Maeda K.  
612 2021. Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from  
613 COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells. *BMJ Open Respir*  
614 *Res* 8:e000830.
- 615 44. Zhou B, She J, Wang Y, Ma X. 2020. Duration of Viral Shedding of Discharged Patients  
616 With Severe COVID-19. *Clin Infect Dis* 71:2240–2242.
- 617 45. Kujawski SA, Wong KK, Collins JP, Epstein L, Killerby ME, Midgley CM, Abedi GR,  
618 Ahmed NS, Almendares O, Alvarez FN, Anderson KN, Balter S, Barry V, Bartlett K,  
619 Beer K, Ben-Aderet MA, Benowitz I, Biggs HM, Binder AM, Black SR, Bonin B, Bozio  
620 CH, Brown CM, Bruce H, Bryant-Genevier J, Budd A, Buell D, Bystritsky R, Cates J,  
621 Charles EM, Chatham-Stephens K, Chea N, Chiou H, Christiansen D, Chu V, Cody S,  
622 Cohen M, Connors EE, Curns AT, Dasari V, Dawson P, DeSalvo T, Diaz G, Donahue M,  
623 Donovan S, Duca LM, Erickson K, Esona MD, Evans S, Falk J, Feldstein LR,  
624 Fenstersheib M, Fischer M, Fisher R, Foo C, Fricchione MJ, Friedman O, Fry A, Galang  
625 RR, Garcia MM, Gerber SI, Gerrard G, Ghinai I, Gounder P, Grein J, Grigg C,  
626 Gunzenhauser JD, Gutkin GI, Haddix M, Hall AJ, Han GS, Harcourt J, Harriman K,  
627 Haupt T, Haynes AK, Holshue M, Hoover C, Hunter JC, Jacobs MW, Jarashow C, Joshi  
628 K, Kamali T, Kamili S, Kim L, Kim M, King J, Kirking HL, Kita-Yarbro A, Klos R,  
629 Kobayashi M, Kocharian A, Komatsu KK, Koppaka R, Layden JE, Li Y, Lindquist S,  
630 Lindstrom S, Link-Gelles R, Lively J, Livingston M, Lo K, Lo J, Lu X, Lynch B, Madoff  
631 L, Malapati L, Marks G, Marlow M, Mathisen GE, McClung N, McGovern O, McPherson  
632 TD, Mehta M, Meier A, Mello L, Moon S sil, Morgan M, Moro RN, Murray J, Murthy R,  
633 Novosad S, Oliver SE, O’Shea J, Pacilli M, Paden CR, Pallansch MA, Patel M, Patel S,  
634 Pedraza I, Pillai SK, Pindyck T, Pray I, Queen K, Quick N, Reese H, Reporter R, Rha B,  
635 Rhodes H, Robinson S, Robinson P, Rolfes MA, Routh JA, Rubin R, Rudman SL,  
636 Sakthivel SK, Scott S, Shepherd C, Shetty V, Smith EA, Smith S, Stierman B, Stoecker  
637 W, Sunenshine R, Sy-Santos R, Tamin A, Tao Y, Terashita D, Thornburg NJ, Tong S,

638 Traub E, Tural A, Uehara A, Uyeki TM, Vahey G, Verani JR, Villarino E, Wallace M,  
639 Wang L, Watson JT, Westercamp M, Whitaker B, Wilkerson S, Woodruff RC, Wortham  
640 JM, Wu T, Xie A, Yousaf A, Zahn M, Zhang J. 2020. Clinical and virologic  
641 characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the  
642 United States. *Nat Med* 26:861–868.

643 46. Perera RAPM, Tso E, Tsang OTY, Tsang DNC, Fung K, Leung YWY, Chin AWH, Chu  
644 DKW, Cheng SMS, Poon LLM, Chuang VWM, Peiris M. 2020. SARS-CoV-2 virus  
645 culture and subgenomic RNA for respiratory specimens from patients with mild  
646 Coronavirus disease. *Emerg Infect Dis* 26:2701–2704.

647 47. Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, Kim JH, Ahn JY, Choi JY,  
648 Yeom J-S. 2020. Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly  
649 Symptomatic Patients with COVID-19 in a Later Phase. *J Clin Med* 9:2924.

650 48. Tong Y, Bao A, Chen H, Huang J, Lv Z, Feng L, Cheng Y, Wang Y, Bai L, Rao W,  
651 Zheng H, Wu Z, Qiao B, Zhao Z, Wang H, Li Y. 2020. Necessity for detection of SARS-  
652 CoV-2 RNA in multiple types of specimens for the discharge of the patients with COVID-  
653 19. *J Transl Med* 18.

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671 **Table 1.** Summary of results on paired specimens collected from 25 symptomatic patients tested  
 672 with the Rheonix, EZ-SARS-CoV-2, and TaqPath COVID-19 assays.

Patient	Days <sup>a</sup>	Rheonix				EZ-SARS-CoV-2 ABI 7500				TaqPath COVID-19 ABI 7500				EZ-SARS-CoV-2 QuantStudio 5				TaqPath COVID-19 QuantStudio 5			
		Specimen:	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S
1 <sup>b</sup>	2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
2 <sup>b</sup>	2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
3 <sup>b</sup>	2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
4 <sup>b</sup>	2	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
5 <sup>b</sup>	3	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
6 <sup>b</sup>	3	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
7 <sup>b</sup>	3	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	-	+	+	+	-
8 <sup>b</sup>	3	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
9 <sup>b</sup>	3	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
10 <sup>b</sup>	3	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
11 <sup>b</sup>	3	+	-	-	-	+	+	+	-	+	-	-	-	+	-	-	-	+	I	I	-
12 <sup>b</sup>	3	-	-	+	-	+	-	-	-	+	-	-	-	+	-	-	-	+	I	-	I
13 <sup>b</sup>	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
14 <sup>b</sup>	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
15 <sup>b</sup>	4	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
16 <sup>b</sup>	4	+	+	+	+	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
17 <sup>b</sup>	4	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
18 <sup>b</sup>	4	+	+	+	-	+	+	+	+	+	+	+	I	+	+	+	+	+	+	+	+
19 <sup>b</sup>	4	+	+	+	-	+	+	+	+	+	+	+	I	+	+	+	-	+	+	+	-
20 <sup>b</sup>	4	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
21 <sup>b</sup>	4	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
22 <sup>b</sup>	4	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
23 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
24 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
25	NA	+	+	+	+	+	+	+	+	+	+	+	I	+	+	+	-	+	+	+	I

673 <sup>a</sup>Days between diagnostic confirmation of SARS-CoV-2 infection and sampling for this study.

674 <sup>b</sup>Virus isolation was attempted with these specimens. ‘NP’ indicates nasopharyngeal swab; ‘AN’  
 675 indicates anterior nares swab; ‘S’ indicates saliva; ‘SL’ indicates sublingual swab; ‘+’ indicates  
 676 SARS-CoV-2 positive; ‘-’ indicates SARS-CoV-2 negative; ‘I’ indicates inconclusive result;  
 677 ‘NA’ indicates not available.

678 **Table 2.** Summary of results on paired specimens collected from 24 asymptomatic patients  
 679 tested with the Rheonix, EZ-SARS-CoV-2, and TaqPath COVID-19 assays.

Patient	Days <sup>a</sup>	Rheonix				EZ-SARS-CoV-2 ABI 7500				TaqPath COVID-19 ABI 7500				EZ-SARS-CoV-2 QuantStudio 5				TaqPath COVID-19 QuantStudio 5			
		NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL
26	1	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
27	2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
28	2	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
29 <sup>b</sup>	2	+	+	+	-	+	+	+	-	+	+	+	I	+	+	+	-	+	+	+	I
30 <sup>b</sup>	2	+	+	+	I	+	+	+	+	+	+	-	+	+	+	-	+	+	+	I	+
31 <sup>b</sup>	2	+	+	+	I	+	+	+	-	+	+	I	+	+	+	-	+	+	+	I	+
32	2	+	-	I	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	-
33	2	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-
34 <sup>b</sup>	3	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
35 <sup>b</sup>	3	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
36 <sup>b</sup>	3	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	I
37 <sup>b</sup>	4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
38 <sup>b</sup>	4	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
39 <sup>b</sup>	4	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
40 <sup>b</sup>	4	+	-	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
41 <sup>b</sup>	5	+	+	+	+	+	+	+	+	+	+	+	I	+	+	+	+	+	+	+	+
42 <sup>b</sup>	5	+	+	+	E	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
43 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
44 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
45 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
46 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
47 <sup>b</sup>	5	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	-
48	NA	+	-	-	-	+	+	+	+	+	+	I	-	+	+	+	-	+	+	-	-
49	NA	+	-	-	+	+	-	-	-	+	-	-	-	+	-	-	-	+	I	-	I

680 <sup>a</sup>Days between diagnostic confirmation of SARS-CoV-2 infection and sampling for this study.

681 <sup>b</sup>Virus isolation was attempted with these specimens. ‘NP’ indicates nasopharyngeal swab; ‘AN’  
 682 indicates anterior nares swab; ‘S’ indicates saliva; ‘SL’ indicates sublingual swab; ‘+’ indicates  
 683 SARS-CoV-2 positive; ‘-’ indicates SARS-CoV-2 negative; ‘I’ indicates inconclusive result; ‘E’  
 684 indicates error; ‘NA’ indicates days not available.

685

686

687

688

689

690 **Table 3.** Summary of results on paired specimens collected from 14 post-symptomatic patients  
 691 tested with the Rheonix, EZ-SARS-CoV-2, and TaqPath COVID-19 assays.

Patient	Days <sup>a</sup>	Rheonix				EZ-SARS-CoV-2 ABI 7500				TaqPath COVID-19 ABI 7500				EZ-SARS-CoV-2 QuantStudio 5				TaqPath COVID-19 QuantStudio 5				
		Specimen:	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL	NP	AN	S	SL
50	4		+	-	-	-	-	-	-	I	-	-	-	-	-	-	-	I	-	-	-	-
51 <sup>b</sup>	5		+	-	+	+	+	-	+	+	-	+	+	+	+	-	+	+	I	+	+	+
52 <sup>b</sup>	5		+	+	-	-	+	+	-	-	+	+	+	-	+	+	-	+	+	+	+	-
53 <sup>b</sup>	5		+	-	-	-	+	+	+	-	+	+	+	-	+	+	+	+	+	+	+	-
54	5		+	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
55	6		+	-	-	-	+	-	-	-	+	-	-	+	+	-	-	I	-	-	-	+
56 <sup>b</sup>	7		+	+	+	-	+	+	-	-	+	+	-	-	+	+	-	+	+	-	-	-
57 <sup>b</sup>	8		+	+	-	-	+	+	+	-	+	I	-	-	+	+	+	+	-	+	-	I
58 <sup>b</sup>	9		+	+	+	-	+	+	+	-	+	+	+	-	+	+	+	+	+	+	+	-
59 <sup>b</sup>	10		+	+	-	-	+	+	+	-	+	+	I	-	+	+	+	+	+	+	+	I
60 <sup>b</sup>	11		+	-	+	-	+	-	-	-	+	I	-	-	-	-	-	I	-	-	-	I
61	12		-	-	-	-	+	-	+	-	I	-	-	-	-	-	-	-	-	-	-	-
62 <sup>b</sup>	23		-	-	-	-	+	-	+	-	+	-	I	-	-	-	-	I	-	I	-	-
63	NA		+	-	+	-	+	-	+	-	+	I	+	-	+	-	+	+	-	+	-	+

692 <sup>a</sup>Days between diagnostic confirmation of SARS-CoV-2 infection and sampling for this study.

693 <sup>b</sup>Virus isolation was attempted with these specimens. ‘NP’ indicates nasopharyngeal swab; ‘AN’  
 694 indicates anterior nares swab; ‘S’ indicates saliva; ‘SL’ indicates sublingual swab; ‘+’ indicates  
 695 SARS-CoV-2 positive; ‘-’ indicates SARS-CoV-2 negative; ‘I’ indicates inconclusive result;  
 696 ‘NA’ indicates days not available.  
 697

698  
 699  
 700  
 701  
 702  
 703  
 704  
 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712

713 **Table 4.** Comparative diagnostic sensitivity of Rheonix, EZ-SARS-CoV-2 (EZ), and TaqPath  
 714 COVID-19 SARS-CoV-2 assays using paired specimens collected from 25 symptomatic  
 715 patients.

Specimen	Rheonix	EZ	TaqPath	EZ	TaqPath
		ABI 7500	ABI 7500	QuantStudio 5	QuantStudio 5
NP	96.00 <sup>a</sup>	100.00	100.00	100.00	100.00
AN	92.00	96.00	92.00	92.00	92.00
S	96.00	96.00	92.00	92.00	92.00
SL	40.00	60.00	48.00	56.00	52.00

716 <sup>a</sup>Percent diagnostic sensitivity

717

718 **Table 5.** Diagnostic sensitivity of Rheonix, EZ-SARS-CoV-2 (EZ), and TaqPath COVID-19  
 719 SARS-CoV-2 assays using paired specimens collected from 24 asymptomatic patients.

Specimen	Rheonix	EZ	TaqPath	EZ	TaqPath
		ABI 7500	ABI 7500	QuantStudio 5	QuantStudio 5
NP	95.83 <sup>a</sup>	91.67	91.67	91.67	91.67
AN	79.17	87.50	91.67	87.50	87.50
S	83.33	91.67	75.00	83.33	75.00
SL	25.00	41.67	33.33	33.33	37.50

720 <sup>a</sup>Percent diagnostic sensitivity

721

722 **Table 6.** Diagnostic sensitivity of Rheonix, EZ-SARS-CoV-2 (EZ), and TaqPath COVID-19  
 723 SARS-CoV-2 assays using paired specimens collected from 14 post-symptomatic patients.

Specimen	Rheonix	EZ	TaqPath	EZ	TaqPath
		ABI 7500	ABI 7500	QuantStudio 5	QuantStudio 5
NP	85.71 <sup>a</sup>	85.71	78.57	64.29	57.14
AN	35.71	42.86	35.71	42.86	35.71
S	35.71	57.14	35.71	50.00	35.71
SL	7.14	7.14	14.29	14.29	14.29

724 <sup>a</sup>Percent diagnostic sensitivity

725

726 **Table 7.** Diagnostic sensitivity of Rheonix, EZ-SARS-CoV-2 (EZ), and TaqPath COVID-19  
 727 SARS-CoV-2 assays using paired specimens collected from 63 patients.

Specimen	Rheonix	EZ	TaqPath	EZ	TaqPath
		ABI 7500	ABI 7500	QuantStudio 5	QuantStudio 5
NP	93.65 <sup>a</sup>	93.65	92.06	88.89	87.30
AN	74.60	80.95	79.37	79.37	77.78
S	77.78	85.71	73.02	79.37	73.02
SL	26.98	41.27	34.92	38.10	38.10

728 <sup>a</sup>Percent diagnostic sensitivity

729 **Table 8.** Result concordance across Rheonix, EZ-SARS-CoV-2, and TaqPath COVID-19 SARS-  
730 CoV-2 assays in paired specimen types.

<b>Specimen type</b>	<b>Concordance across platforms (%)</b>
NP	87.30
AN	82.54
Saliva	74.60
SL	61.90

731

732

733 **Table 9.** SARS-CoV-2 detection from specimens relative to NP swabs using paired specimens  
734 collected from 63 patients.

<b>Specimen</b>	<b>Rheonix</b>	<b>EZ ABI 7500</b>	<b>TaqPath ABI 7500</b>	<b>EZ QuantStudio 5</b>	<b>TaqPath QuantStudio 5</b>	<b>All platforms combined</b>
NP detected <sup>a</sup>	59	59	58	56	55	62
<b>Percent detected relative to NP</b>						
AN	79.66	86.44	84.48	89.29	89.09	83.87
S	81.36	89.83	79.31	87.50	83.64	95.16
SL	28.81	42.37	37.93	42.86	41.82	51.61

735 <sup>a</sup>Number of SARS-CoV-2-positive NP specimens detected

736

737

738

739

740

741

742

743

744


745

746

747


748

749




750

751 **Figure 1.** Paired specimen sets collected for this study. Specimens were excluded if testing was  
752 not performed on all platforms and if SARS-CoV-2 RNA was not detected from any specimen  
753 by any platform. After filtering, 63 sets of paired specimens were used for analyses. Of those, 50  
754 sample sets were used for virus isolation.




755

756 **Figure 2.** SARS-CoV-2 cycle threshold (Ct) value across paired specimen types collected from  
757 63 positive individuals. SARS-CoV-2 cycle threshold (Ct) values obtained using the EZ-SARS-  
758 CoV-2 assay on the ABI 7500 platform are shown on the y-axis. Specimen types included  
759 nasopharyngeal swabs (NP, n=59 with positive Ct values), anterior nares swabs (AN, n=51 with  
760 positive Ct values), saliva (S, n=54 with positive Ct values), and sublingual swabs (SL, n=26  
761 with positive Ct values), and are shown on the x-axis. The horizontal line in each specimen type  
762 indicates the median value (NP=26.13, AN=26.19, S=26.26, SL=0; 0 Ct value indicates not  
763 detected).






764  
765 **Figure 3.** SARS-CoV-2 cycle threshold (Ct) values within sets of respiratory and oral specimens  
766 collected from 24 positive individuals. SARS-CoV-2 cycle threshold (Ct) values obtained using  
767 the EZ-SARS-CoV-2 assay on the ABI 7500 platform are shown on the y-axis. Specimen types  
768 are shown on the x-axis (NP = nasopharyngeal swab, AN = anterior nares swab, S = saliva, SL =  
769 sublingual swab). Each paired set collected from an individual patient is distinguished by a  
770 different color and symbol combination.



771  
772 **Figure 4.** Success of SARS-CoV-2 isolation by specimen type. Specimen types are shown along  
773 the x-axis (NP = nasopharyngeal swab, AN = anterior nares swab, S = saliva, SL = sublingual  
774 swab) and the percent of specimens yielding positive SARS-CoV-2 virus isolation is shown on  
775 the y-axis.

776

777



778 **Figure 5.** SARS-CoV-2 isolation  
779 from paired respiratory and oral  
780 specimens collected from 50  
781 positive individuals. SARS-CoV-  
782 2 cycle threshold (Ct) values are  
783 shown on the y-axis. Days  
784 between initial diagnostic test  
785 and specimen collection for this  
786 study are on the x-axis.  
787 Successful virus isolation  
788 (filled/black symbols) or lack of  
789 virus isolation (open symbols) is